logo
episode-header-image
Aug 2022
21m 41s

Why We’re In a ‘Golden Age’ of Life Scie...

GOLDMAN SACHS
About this episode
The business of life sciences came into sharp focus after the pandemic highlighted the effectiveness of mRNA vaccines in protecting people against COVID. But what exactly is life sciences and is the recent market weakness a threat to future innovation — or an opportunity? In the latest episode of Exchanges at Goldman Sachs, Amit Sinha, head of Life Sciences ... Show More
Up next
Sep 23
Why Markets May Be Pricing in Too Many Fed Rate Hikes
Markets may be pricing in more tightening by the Federal Reserve than is warranted due to a divergence playing out in the economy, according to Goldman Sachs Vice Chairman and former Dallas Fed President Rob Kaplan. In the Goldman Sachs Exchanges podcast, Kaplan notes that while ... Show More
18m 24s
Sep 18
Rich Friedman on the Rise of Private Markets and AI Investing
Rich Friedman, chairman of Goldman Sachs Asset Management, says there are still plenty of investment opportunities in private equity, even as private markets have grown far larger than he would have imagined a few decades ago. In this conversation with Alison Mass, chairman of In ... Show More
42m 23s
Sep 15
Why Global Bond Yields Are Surging
Government bond yields have surged to multi-decade highs across the US, UK, Germany, and Japan. George Cole, head of European Rates Strategy for Goldman Sachs Research, says there is a range of factors behind the bond sell-off—from swelling fiscal deficits and borrowing tied to i ... Show More
25m 26s
Recommended Episodes
Sep 2021
The future of vaccines
The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller ... Show More
17m 28s
Jun 2024
Leading with science: A deep dive on biotech
In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ... Show More
17m 43s
Sep 2023
Business and science: How risky is SynBio?
For all the exciting developments in the synthetic biology industry, there are also concerns. People can edit genes in their garages these days, so who’s regulating this space?Plus - we’ll hear about the exciting new business models with biology at their core, including one of th ... Show More
17m 26s
Sep 2023
Business and science: What you need to know about SynBio
In this week’s series focusing on business and science, we start things off by looking at the world of synthetic biology.The industry is estimated to be worth around $30bn in the next few years, but how is that money actually made?We speak to businesses across the world to find o ... Show More
17m 28s
Aug 2020
430. Will a Covid-19 Vaccine Change the Future of Medical Research?
<p>We explore the science, scalability, and (of course) economics surrounding the global vaccine race. Guests include the chief medical officer of the first U.S. firm to go to Phase 3 trials with a vaccine candidate; a former F.D.A. commissioner who’s been warning of a pandemic f ... Show More
58m 24s
Jan 2024
The Insight: Conversations – Walking into the Unknown with Howard Marks, David Rosenberg, and Aman Kumar
What is a “normal” investment environment? What might a recession in 2024 mean for liquid credit? What’s happening in life sciences lending today? Find out by listening to the latest episode of The Insight: Conversations with Howard Marks (Co-Chairman), David Rosenberg (Co-Portfo ... Show More
35m 13s
Nov 2020
Biden's Pandemic Plan And The Vaccine Effect On The Stock Market | WBW
<p>In this episode of Millionaire Mindcast, we have the dynamic duo covering what happen this past week with economy, Biden's pandemic plan and how is the Markets reacting to the latest news on a Covid Vaccine. This and more on today's episode. Tune-in, Enjoy!&nbsp;</p> <p>Enter ... Show More
44m 26s
Nov 2020
The Vaccine (EP.176)
On this week's show we discuss what a vaccine would mean for the markets and economy, why a post-pandemic market will be so difficult to handicap, the potential for a massive boom post-vaccine, market moves after the election, corporate America as our strongest institution, why t ... Show More
36m 57s